Rani Therapeutics/$RANI
1D1W1MYTD1Y5YMAX
About Rani Therapeutics
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
- Ticker
- $RANI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 70
- Headquarters
- San Jose, United States
- Website
- www.ranitherapeutics.com
RANI Metrics
BasicAdvanced
$99M
-
-$0.22
0.70
-
Price and volume
Market cap
$99M
Beta
0.7
52-week high
$3.87
52-week low
$0.44
Average daily volume
925K
Financial strength
Current ratio
5.313
Quick ratio
5.23
Long term debt to equity
4.626
Total debt to equity
7.396
Interest coverage (TTM)
-28.22%
Profitability
EBITDA (TTM)
-32.237
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-618.02%
Operating margin (TTM)
-675.80%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-52.99%
Return on equity (TTM)
-172.15%
Valuation
Price to revenue (TTM)
24.286
Price to book
2.45
Price to tangible book (TTM)
2.45
Price to free cash flow (TTM)
-5.823
Free cash flow yield (TTM)
-17.17%
Free cash flow per share (TTM)
-0.147
Growth
Revenue change (TTM)
306.42%
Earnings per share change (TTM)
-75.92%
3-year earnings per share growth (CAGR)
-45.95%
What the Analysts think about RANI
Analyst ratings (Buy, Hold, Sell) for Rani Therapeutics stock.
RANI Financial Performance
Revenues and expenses
RANI Earnings Performance
Company profitability
RANI News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.